Cytiva's Biopharma Resilience Index measured the ability of different nations to meet their domestic biotherapeutic needs. The Index revealed that biomanufacturing agility is a critical element to establishing this resilience and we've witnessed this during COVID-19 vaccines.
We have learned from COVID-19 vaccine development that the time to develop and manufacture a vaccine is paramount to saving lives. In addition, variants may arise which further underpins the criticality of vaccine responsiveness speed. Thus, the ideal platform for vaccine development should be fast, versatile, in terms of applicable to different disease and variant target antigens, and easy to scale manufacturing either centrally to mazimize efficiencies or e locally to minimize logistical issue in the distribution of a vaccine. In this presentation, we examine the role of mRNA technology as a rapid pandemic response platform and explore the next generation self-amplifying RNA technology. The role of lipid nanoparticles as RNA delivery platform and the manufacturing method will also be discussed. Participants will gain insights into the major pillars required for the development of RNA vaccines, and how these can address future bottle necks to the provision of vaccines to address future and current pandemics.
Learning Objectives / Topics
Participants will be able to:
A recognize the key challenges in vaccine development
B describe the benefits of RNA vaccines in the context of rapid pandemic response
C describe the benefits of self-amplifying RNA compared to non-amplifying RNA
D identify the tools required to develop RNA vaccines
E select a suitable manufacturing method for rapid development of non-viral vaccines
Marketing Director Asia Pacific Cytiva
Anastasia Darwitan, Ph.D.
Field Application Scientist (APAC) Precision NanoSystems, Inc.